Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 and Hydroxychloroquine in Advanced Renal Cell Carcinoma
NCT01510119Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Sep 2011
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of hydroxychloroquine in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Abramson Cancer Center. Primary endpoint: Progression-Free Survival at 6 months. Started Sep 2011; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT01510119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01510119.